136 related articles for article (PubMed ID: 34890568)
1. Persistent N2 After Induction Is Not a Contraindication to Surgery for Lung Cancer.
Andrews WG; Louie BE; Castiglioni M; Dhamija A; Farivar AS; Chansky J; White PT; Aye RW; Vallières E; Bograd AJ
Ann Thorac Surg; 2022 Aug; 114(2):394-400. PubMed ID: 34890568
[TBL] [Abstract][Full Text] [Related]
2. Surgical multimodality treatment for baseline resectable stage IIIA-N2 non-small cell lung cancer. Degree of mediastinal lymph node involvement and impact on survival.
Decaluwé H; De Leyn P; Vansteenkiste J; Dooms C; Van Raemdonck D; Nafteux P; Coosemans W; Lerut T
Eur J Cardiothorac Surg; 2009 Sep; 36(3):433-9. PubMed ID: 19502079
[TBL] [Abstract][Full Text] [Related]
3. [Lung cancer: is surgery an option for persisting N2 after induction therapy?].
Haager B; Osei-Agyemang T; Passlick B; Wiesemann S
Zentralbl Chir; 2015 Feb; 140(1):99-103. PubMed ID: 25076164
[TBL] [Abstract][Full Text] [Related]
4. Surgical resection for residual N2 disease after induction chemotherapy.
Port JL; Korst RJ; Lee PC; Levin MA; Becker DE; Keresztes R; Altorki NK
Ann Thorac Surg; 2005 May; 79(5):1686-90. PubMed ID: 15854955
[TBL] [Abstract][Full Text] [Related]
5. Nodal stage after induction therapy for stage IIIA lung cancer determines patient survival.
Bueno R; Richards WG; Swanson SJ; Jaklitsch MT; Lukanich JM; Mentzer SJ; Sugarbaker DJ
Ann Thorac Surg; 2000 Dec; 70(6):1826-31. PubMed ID: 11156079
[TBL] [Abstract][Full Text] [Related]
6. Is surgery indicated in patients with stage IIIa lung cancer and mediastinal nodal involvement?
Bakir M; Fraser S; Routledge T; Scarci M
Interact Cardiovasc Thorac Surg; 2011 Sep; 13(3):303-10. PubMed ID: 21685220
[TBL] [Abstract][Full Text] [Related]
7. Significantly favourable outcome for patients with non-small-cell lung cancer stage IIIA/IIIB and single-station persistent N2 (skip or additionally N1) disease after multimodality treatment.
Stamatis G; Müller S; Weinreich G; Schwarz B; Eberhardt W; Pöttgen C; Aigner C
Eur J Cardiothorac Surg; 2022 Jan; 61(2):269-276. PubMed ID: 34368849
[TBL] [Abstract][Full Text] [Related]
8. Transesophageal ultrasound-guided fine-needle aspiration for the mediastinal restaging of non-small cell lung cancer.
von Bartheld MB; Versteegh MI; Braun J; Willems LN; Rabe KF; Annema JT
J Thorac Oncol; 2011 Sep; 6(9):1510-5. PubMed ID: 21642873
[TBL] [Abstract][Full Text] [Related]
9. Prognostic stratification of stage IIIA-N2 non-small-cell lung cancer after induction chemotherapy: a model based on the combination of morphometric-pathologic response in mediastinal nodes and primary tumor response on serial 18-fluoro-2-deoxy-glucose positron emission tomography.
Dooms C; Verbeken E; Stroobants S; Nackaerts K; De Leyn P; Vansteenkiste J
J Clin Oncol; 2008 Mar; 26(7):1128-34. PubMed ID: 18309948
[TBL] [Abstract][Full Text] [Related]
10. A Validation Study of the Recommended Change in Residual Tumor Descriptors Proposed by the International Association for the Study of Lung Cancer for Patients With pN2 NSCLC.
Yun JK; Lee GD; Choi S; Kim YH; Kim DK; Park SI; Kim HR
J Thorac Oncol; 2021 May; 16(5):817-826. PubMed ID: 33607310
[TBL] [Abstract][Full Text] [Related]
11. Prognosis of multi-level N2-positive non-small cell lung cancer according to lymph node staging using endobronchial ultrasound-transbronchial biopsy.
Yoon HY; Lee JC; Kim SW; Kim HR; Kim YH; Choi SH; Kim SS; Song SY; Choi EK; Jang SJ; Choi CM
Thorac Cancer; 2018 Jun; 9(6):684-692. PubMed ID: 29607613
[TBL] [Abstract][Full Text] [Related]
12. Clinical Predictors of Persistent Mediastinal Nodal Disease After Induction Therapy for Stage IIIA N2 Non-Small Cell Lung Cancer.
Kamel MK; Rahouma M; Ghaly G; Nasar A; Port JL; Stiles BM; Nguyen AB; Altorki NK; Lee PC
Ann Thorac Surg; 2017 Jan; 103(1):281-286. PubMed ID: 27623273
[TBL] [Abstract][Full Text] [Related]
13. Surgical therapeutic strategy for non-small cell lung cancer with mediastinal lymph node metastasis (N2).
Ma Q; Liu D; Guo Y; Shi B; Song Z; Tian Y
Zhongguo Fei Ai Za Zhi; 2010 Apr; 13(4):342-8. PubMed ID: 20677562
[TBL] [Abstract][Full Text] [Related]
14. Surgery after induction chemotherapy in stage IIIA-N2 non-small cell lung cancer: why pneumonectomy should be avoided.
Kappers I; van Sandick JW; Burgers SA; Belderbos JS; van Zandwijk N; Klomp HM
Lung Cancer; 2010 May; 68(2):222-7. PubMed ID: 19664843
[TBL] [Abstract][Full Text] [Related]
15. Clinical implications of uncertain resection in scenarios of metastasis of the highest or most distant mediastinal lymph node station following surgical treatment of non-small-cell lung cancer.
Park SY; Byun GE; Lee CY; Lee JG; Kim DJ; Paik HC; Chung KY
Lung Cancer; 2019 Dec; 138():1-5. PubMed ID: 31593893
[TBL] [Abstract][Full Text] [Related]
16. Survival Analysis of Surgically Resected ypN2 Lung Cancer after Neoadjuvant Therapy.
İşgörücü Ö; Citak N
Thorac Cardiovasc Surg; 2023 Apr; 71(3):206-213. PubMed ID: 35235990
[TBL] [Abstract][Full Text] [Related]
17. Prognostic Significance of the Number of Metastatic pN2 Lymph Nodes in Stage IIIA-N2 Non-Small-Cell Lung Cancer After Curative Resection.
Yoo C; Yoon S; Lee DH; Park SI; Kim DK; Kim YH; Kim HR; Choi SH; Kim WS; Choi CM; Jang SJ; Song SY; Kim SS; Choi EK; Lee JC; Suh C; Lee JS; Kim SW
Clin Lung Cancer; 2015 Nov; 16(6):e203-12. PubMed ID: 25997733
[TBL] [Abstract][Full Text] [Related]
18. Beyond Margin Status: Population-Based Validation of the Proposed International Association for the Study of Lung Cancer Residual Tumor Classification Recategorization.
Osarogiagbon RU; Faris NR; Stevens W; Fehnel C; Houston-Harris C; Ojeabulu P; Akinbobola OA; Lee YS; Ray MA; Smeltzer MP
J Thorac Oncol; 2020 Mar; 15(3):371-382. PubMed ID: 31783180
[TBL] [Abstract][Full Text] [Related]
19. Role of surgery in N2 NSCLC: pros.
Shien K; Toyooka S
Jpn J Clin Oncol; 2016 Dec; 46(12):1168-1173. PubMed ID: 27655902
[TBL] [Abstract][Full Text] [Related]
20. The impact of residual multi-level N2 disease after induction therapy for non-small cell lung cancer.
Sawabata N; Keller SM; Matsumura A; Kawashima O; Hirono T; Osaka Y; Maeda H; Fukai S; Kawahara M;
Lung Cancer; 2003 Oct; 42(1):69-77. PubMed ID: 14512190
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
